Loading
Life sciences · Journal article
Frontiers in Genetics · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Radiotherapy (RT) is evolving from local cytotoxicity to systemic immunomodulation. Acting as an in situ vaccine, RT initiates antitumor immunity via immunogenic cell death and cGAS-STING activation. However, RT concurrently triggers counter-regulatory immunosuppression—upregulating PD-L1/TGF-β, expanding Tregs/MDSCs, and inducing T-cell exhaustion—limiting durable systemic control. Methods We integrate preclinical mechanisms and key clinical evidence for radioimmunotherapy combinations. We analyze how radiation dose, fractionation, and delivery techniques remodel the tumor immune microenvironment and outline matching therapeutic strategies Key findings Optimal combination requires balancing local tumor control with systemic immune activation while preserving lymphoid reserves. Consolidation durvalumab following concurrent chemoradiotherapy has been shown to improve survival in patients with unresectable stage III non-small cell lung cancer, and SBRT combined with PD-(L)1 blockade has demonstrated benefits in oligometastatic settings. Conversely, radioimmunotherapy combinations have yielded disappointing outcomes in extensive-stage small cell lung cancer and head and neck cancers. Low-dose RT and novel spatial-fractionation strategies offer emerging solutions to reverse immune exclusion. Conclusion Efficacy hinges on converting RT-induced immunoadaptation into productive antitumor immunity. Future progress demands biomarker-driven patient selection (e.g., tumor mutational burden, chromosomal instability) and precise orchestration of multi-modality timing. Transitioning toward “immunologically guided precision radiotherapy” will transform RT from a static local therapy into a dynamic component of systemic cancer care.